Millennium Management LLC Acquires 156,959 Shares of Compugen Ltd. (NASDAQ:CGEN)

Millennium Management LLC boosted its holdings in shares of Compugen Ltd. (NASDAQ:CGEN) by 77.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 359,397 shares of the biotechnology company’s stock after acquiring an additional 156,959 shares during the quarter. Millennium Management LLC owned 0.40% of Compugen worth $550,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in CGEN. Commonwealth Equity Services LLC bought a new stake in shares of Compugen in the 4th quarter valued at $32,000. Jane Street Group LLC bought a new stake in shares of Compugen in the 4th quarter valued at $81,000. Oppenheimer & Co. Inc. boosted its stake in shares of Compugen by 187.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 36,252 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Compugen in the 4th quarter valued at $103,000. Finally, Marshall Wace LLP boosted its stake in shares of Compugen by 84.9% in the 4th quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 40,494 shares during the last quarter. 12.22% of the stock is owned by institutional investors.

Compugen Stock Up 1.8%

Compugen stock opened at $1.74 on Monday. Compugen Ltd. has a 12-month low of $1.13 and a 12-month high of $2.66. The firm’s fifty day moving average is $1.41 and its 200 day moving average is $1.68. The company has a market capitalization of $155.27 million, a PE ratio of 87.00 and a beta of 2.54.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, May 19th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Compugen had a net margin of 2.67% and a return on equity of 2.62%. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $3.70 million. During the same quarter in the previous year, the firm earned ($0.08) EPS. Sell-side analysts expect that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.